If you pick your child up under the arms you should be able to get a solid grip and swing him up. A child with low muscle tone (child's muscles seem loose and slack, he has what's called low muscle tone) might feel like he's slipping through your grasp.Toddlers with low muscle tone don't move very efficiently.More serious causes, such as Down syndrome and muscular dystrophy, would already have been diagnosed by the time a child reached toddlerhood.
The most well known of the muscular dystrophies is Duchenne muscular dystrophy (DMD) usually symptoms include weakness and wasting of muscles of the hands, forearms, and lower legs; progress is slow; rarely leads to total incapacity.In a child who is otherwise healthy and meeting normal developmental milestones, hypotonia can mean simply low muscle tone and increased flexibility or laxity of ligaments; in one who is severely ill it can mean an inability to sit up, crawl, walk, eat correctly, etc.
Muscular dystrophy (MD) is a group of inherited diseases that cause the muscles to weaken and degenerate. The muscles lack a key protein needed to work properly. The body loses muscle tissue and replaces it with fat and connective tissue. This can make the muscles look larger than normal. Despite the size of the muscles, children with muscular dystrophy have significant muscle weakness which makes walking difficult or even impossible. Currently, there is no cure.
There are many forms of muscular dystrophy. Duchenne muscular dystrophy is the most common type and the most severe childhood form of the disease. In cases of Duchenne muscular dystrophy, symptoms usually begin to appear around age 5, as the pelvic muscles begin to weaken. Most kids with this form of MD need to use a wheelchair by age 12. Over time, their muscles weaken in the shoulders, back, arms, and legs. Eventually, the respiratory muscles are affected, and a ventilator is required to assist breathing. Kids who have Duchenne muscular dystrophy typically have a life span of about 20 years. The life span for people with the disease is usually shortened to the 20s.
This form of MD occurs because of a problem with the gene that makes dystrophin. Without this protein, the muscles break down and a child becomes weaker.Most boys with DMD walk alone at a later age than average, and even then in an unusual manner. They may frequently fall, have difficulty rising from the ground, or difficulty climbing stairs.Sometimes there is intellectual handicap, which, although rare in boys with DMD, is more frequent than in other children. Duchenne muscular dystrophy (DMD) has an effect on posture and gait -- the way the boy stands, walks and runs -- especially up hills or steps.
Calf muscles, and sometimes other muscles, look very well developed or excessively large, while other muscles are poorly developed.Walking may be described as waddling.Whether standing still or walking, the boy usually has an exaggeration of the forward curve of the lower part of the back, sometimes called sway-back. The medical term for this is lordosis.Later development indicates a tendency to stand and walk on the forward part of the foot with the heels off the ground.
Myotonic dystrophy is passed along in a pattern called autosomal dominant inheritance. If either parent carries the defective gene for myotonic dystrophy, there's a 50 percent chance the disorder will be passed along to a child.
Some of the less common types of muscular dystrophy are passed along in the same inheritance pattern that marks Duchenne and Becker's muscular dystrophies. Other types of muscular dystrophy can be passed on from generation to generation and affect males and females equally. Still others require a defective gene from both parents.
A deficiency of the protein dystrophin has recently been shown to be the probable cause of Duchenne's muscular dystrophy.
Recently researchers sought to determine the relation between the clinical phenotype and the status of dystrophin in muscle-biopsy specimens from 103 patients with various neuromuscular disorders. We found very low levels (less than 3 percent of normal levels) or no dystrophin in the severe Duchenne phenotype (35 of 38 patients), low concentrations of dystrophin in the intermediate (outlier) phenotype (4 of 7), and dystrophin of abnormal molecular weight in the mild Becker phenotype (12 of 18). Normal levels of dystrophin of normal molecular weight were found in nearly all the patients (38 of 40) with 20 other neuromuscular disorders we studied. These data show the clinical consequences of both quantitative alterations (in Duchenne's and intermediate dystrophy) in a single protein. The biochemical assay for dystrophin should prove helpful in delineating myopathies that overlap clinically with Duchenne's and Becker's dystrophies, and it shows promise as an accurate diagnostic tool.
Currently,scientists are focused on the mechanisms of muscular dystrophy associated with mutations in the transmembrane dystrophin-glycoprotein complex. There has been an explosion of genetic evidence indicating that the central protein in this complex, dystroglycan, is the key player in a number of muscular dystrophies.In addition, protein complexes containing some of the components of the dystrophin-glycoprotein complex in muscle are expressed throughout the body. Human patients and mouse models with defects in dystroglycan function have altered neuronal migration, synaptic function, peripheral nerve structure and function, eye development and function, and neuromuscular junction formation.
Duchenne muscular dystrophy with associated growth hormone deficiency .Study over a patient with Duchenne muscular dystrophy [DMD] and growth hormone [GH] deficiency is described who had no clinical evidence of muscular weakness before initiation of GH replacement therapy. Treatment with human GH resulted in appearance of symptoms of easy fatigability and proximal muscle weakness. Thorough investigations including serum creatinine phosphokinase [CK] levels is recommended in every patient with GH deficiency before starting GH replacement therapy.
A comparative study of automatic electromyogram analysis [power spectral analysis] and manual measurements of the individual motor units potentials parameters in normal and Duchenne muscular dystrophy patients was performed to assess the diagnostic yield of both methods.The net result of this study is that the electromyogram power spectrum has diagnostic possibilities in the muscles, which showed normal, or few motor unit potential changes.
Duchenne's muscular dystrophy (DMD) is known to delay children's development of movement and coordination, but now new research indicates that it may also slow language development.
DMD occurs in roughly 1 of every 3500 male births, according to the report in The Journal of Pediatrics. The disease is thought of as mainly affecting muscles, because children become progressively weaker. However, slowness with words has been described in children and adolescents with the disease.
To investigate, Dr. Veronica J. Hinton, from Columbia University in New York, and colleagues analyzed parents' reports to assess the achievement of 10 common developmental milestones by 130 children with DMD and 59 unaffected siblings. The milestones included smiling, sitting, crawling, standing, walking, speaking, forming sentences, being bowel trained, being bladder trained, and reading.
The team found that the children with DMD were more likely than their siblings to experience delays in both motor and language development. The results also indicate that DMD kids classified as late walkers or late talkers had lower cognition scores than those who walked or talked at the expected age.
"The current findings underscore the need for early intervention services in this population," Hinton and her associates conclude. "The initiation of an early intervention may help limit later learning problems, potentially enhancing the quality of life for a group of children who face adversity in the form of enormous physical and emotional challenges."
|
| 127 : vote(s) so far
| Cast your vote: